Unknown (target of m170 monoclonal antibody, described as “adenocarcinoma-associated antigen” but not definitively identified or named in available literature) (null)

The adenocarcinoma-associated antigen recognized by m170 monoclonal antibody is a tumor-associated cell surface antigen targeted by the murine monoclonal antibody m170, which has been exploited in radioimmunotherapy trials for metastatic prostate and breast adenocarcinoma. While m170 can selectively bind to these cancer cells and deliver conjugated cytotoxic radionuclides (^111In for imaging and ^90Y for therapy), the antigen’s precise molecular identity, structure, and physiological function have not been published in accessible literature. The target is not a named receptor, enzyme, or transporter, but rather an undefined cell-surface protein associated with adenocarcinoma, serving as a means for selective cancer targeting in therapeutic and imaging applications.

Other names

m170-target antigenAdenocarcinoma-associated antigen (as recognized by m170)null

Antibody-targeted radioimmunotherapy: Monoclonal antibody m170 delivers cytotoxic radiation (from ^111In or ^90Y conjugates) selectively to cancer cells expressing the antigen, causing cell death. Combination with chemotherapy: adding paclitaxel to increase anticancer efficacy and possibly act synergistically with antibody-targeted radiation.